@ODExpertGroup

Established in 2020, the European Expert Group on Orphan Drug Incentives brings together representatives of the broad rare diseases community.

[@ODExpertGroup @odexpertgroup]

🗣️We are delighted to announce the speakers of our workshop on March 22! We look forward to an insightful and fruitful conversation.
Register here!
https://t.co/cjmzIpxbAz

[@ODExpertGroup @odexpertgroup]

"The expertise of panelists stimulated interesting discussions on the future of healthcare and innovation for people living with a rare disease, in the multidisciplinary and cross-sectorial framework characteristic of the OD Expert Group"
⬇️Read more here!
https://t.co/V3IOhlYzOT

[@ODExpertGroup @odexpertgroup]

💡LESS THAN 1 WEEK LEFT!

On Thursday, June 29, our experts and institutional representatives will address the question of how to create a resilient ecosystem for rare diseases through the Pharma revision and an EU HTA... don't miss it!
Register today! https://t.co/LvKgn8kkkY

[@ODExpertGroup @odexpertgroup]

📢SAVE THE DATE - 29 JUNE📢

Join us for an event that brings together a diverse group of rare disease experts to discuss and propose policy recommendations for improving the European legislative framework and HTA for orphan drugs.

⬇️Register today!

https://t.co/Ml1U48pHOD

[@ODExpertGroup @odexpertgroup]

On 26 April, the Commission published the EU Pharma Package, revising the OMP Regulation. While several provisions represent a step in the right direction, others risk not reaching their objective to address the existing gap of 95%.
https://t.co/aXQzsr61CP

[@ODExpertGroup @odexpertgroup]

🔎OD EXPERT GROUP'S PROPOSALS
Let’s talk about Significant Benefit! 📷@EUCOPE
@eurordis

https://t.co/SnWTbz4Ap8

[@ODExpertGroup @odexpertgroup]

🔎OD EEXPERT GROUP'S PROPOSALS

💡 Let’s start with the modulation of incentives!
🎧Listen to our expert Julia Wahl
@EUCOPE
@eurordis
https://t.co/wQDGzA8zgz

[@ODExpertGroup @odexpertgroup]

On March 22, MEP Pernille Weiss hosted us in the European Parliament to present our policy proposals for the revision of the EU Pharma legislation.

⏩The video is now available, watch it now in case you missed it!

https://t.co/QJhPleg1Iq

[@ODExpertGroup @odexpertgroup]

❗️Only one hour left to the OD Expert Group workshop in Parliament.

See you at 13:00 in Room ANTALL 6Q1 or follow the live stream here https://t.co/GRXwoIjsta

[@ODExpertGroup @odexpertgroup]

📢The day has almost come! Tomorrow the OD Expert group Group will present its policy proposals in the European Parliament, hosted by MEP @WeissPernille .
Read the agenda here.
https://t.co/7NnjJuaoIC
⬇️It’s not too late to register at the link below!
https://t.co/cjmzIpxbAz

[@ODExpertGroup @odexpertgroup]

📖 The OD Expert Group is about to publish its full report on the policy proposals for the OMP revision!
Find out more about our work and vision for the legislative revision during our workshop in the Parliament on March 22 (13:00 -14:30)
⬇️Register here
https://t.co/cjmzIpxbAz

[@ODExpertGroup @odexpertgroup]

📅 Mark your calendars! On March 22, the OD Expert Group will present its #policyproposals on the upcoming revision of the #OMPRegulation in the #EuropeanParliament, hosted by MEP @WeissPernille.

⬇️Don’t miss out! Register here:
https://t.co/cjmzIpxbAz

[@ODExpertGroup @odexpertgroup]

📅 Mark your calendars! On March 22, the OD Expert Group will present its #policyproposals on the upcoming revision of the #OMPRegulation in the #EuropeanParliament, hosted by MEP @WeissPernille.

⬇️Don’t miss out! Register here:
https://t.co/cjmzIpxbAz

[@ODExpertGroup @odexpertgroup]

After more than two years of close #cooperation, we are honoured to announce the launch of our policy #proposals at a workshop in the #EuropeanParliament. The event will be hosted by MEP @WeissPernille on March 22, 13.00-14.30 at the European Parliament

Stay tuned for more info

[@ODExpertGroup @odexpertgroup]

Let's talk about demand and pricing!
💡Improving #consistency and #predictability of demand and #pricing for #OMPs is vital to the development of #innovativetreatments. We developed a set of policy solutions where incentives are fully aligned to the market access stage.

[@ODExpertGroup @odexpertgroup]

Let's talk about Regulatory Approval

📖Uncertainties in the #regulatorypathway often represent an obstacle to #innovation. That's why it is pivotal to strengthen cooperation between the #EMA and developers.
⬇️Read more about our proposal

[@ODExpertGroup @odexpertgroup]

Let's talk about Incentives & Rewards
📈The current financial #incentives for #OMP are insufficient to focus development on areas of #unmetneed. That's why we propose a re-modulation of #marketexclusivity and the introduction of new incentives. Read more about it

[@ODExpertGroup @odexpertgroup]

Let's start the new year with insightful discussions on R&D

🔬To improve the R&D ecosystem for basic #research and #clinical development, it is essential to increase funds and #incentives for #transnationalresearch on #rarediseases and improve infrastructure for R&D stakeholders

[@ODExpertGroup @odexpertgroup]

✨ Happy New Year from the OD Expert Group

We look forward to continuing our collaboration in 2023 and presenting our ideas to improve the debate on rare diseases. Stay connected to follow our work!

[@ODExpertGroup @odexpertgroup]

🎤 Time to talk with our experts!

Michael Schlander is Professor of Health Economics at the University of Heidelberg /Head of Division, DFKZ

https://t.co/rCHcKCQcN6